Palisade Bio Inc
NASDAQ:PALI
Operating Margin
Palisade Bio Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Palisade Bio Inc
NASDAQ:PALI
|
7.4m USD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
660.9B USD |
42%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
424B USD |
26%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
203.6B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
182B GBP |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
46%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
194B CHF |
33%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
211.9B USD |
38%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.5B USD |
29%
|
Palisade Bio Inc
Glance View
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. The company is headquartered in Carlsbad, California and currently employs 13 full-time employees. The company went IPO on 2006-12-20. The firm is focused on discovering, developing, and commercializing oral therapies that target diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal (GI) tract. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the digestive enzyme inhibitor, tranexamic acid, intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from, among other things, reduced blood flow to the intestine, infections, or due to surgery. Its LB1148 has been advanced to Phase III clinical trials for the return of bowel function indication, which is a protease inhibitor that helps to restore bowel function and reduce abdominal adhesions following surgery.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Palisade Bio Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet